CA3107079A1 - Pyridone a2r antagonists - Google Patents
Pyridone a2r antagonists Download PDFInfo
- Publication number
- CA3107079A1 CA3107079A1 CA3107079A CA3107079A CA3107079A1 CA 3107079 A1 CA3107079 A1 CA 3107079A1 CA 3107079 A CA3107079 A CA 3107079A CA 3107079 A CA3107079 A CA 3107079A CA 3107079 A1 CA3107079 A1 CA 3107079A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- group
- compound
- a2ar
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862711273P | 2018-07-27 | 2018-07-27 | |
| US62/711,273 | 2018-07-27 | ||
| PCT/US2019/043608 WO2020023846A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3107079A1 true CA3107079A1 (en) | 2020-01-30 |
Family
ID=69182367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3107079A Pending CA3107079A1 (en) | 2018-07-27 | 2019-07-26 | Pyridone a2r antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12064433B2 (enExample) |
| EP (1) | EP3829581B1 (enExample) |
| JP (1) | JP7394831B2 (enExample) |
| KR (1) | KR102809468B1 (enExample) |
| CN (1) | CN112996509B (enExample) |
| AU (1) | AU2019312296B2 (enExample) |
| CA (1) | CA3107079A1 (enExample) |
| ES (1) | ES2982326T3 (enExample) |
| PL (1) | PL3829581T3 (enExample) |
| WO (1) | WO2020023846A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113795267A (zh) | 2019-03-12 | 2021-12-14 | 艾库斯生物科学有限公司 | 致癌基因驱动的癌症的治疗 |
| WO2020205527A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| CN119118872A (zh) | 2020-03-19 | 2024-12-13 | 艾库斯生物科学有限公司 | 作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物 |
| JP2021183587A (ja) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | 複素環化合物 |
| KR20230026312A (ko) | 2020-06-17 | 2023-02-24 | 아르커스 바이오사이언시즈 인코포레이티드 | Cd73 억제제의 결정형 및 이의 용도 |
| KR20230062845A (ko) | 2020-09-03 | 2023-05-09 | 이뮨센서 테라퓨틱스, 인코포레이티드 | 퀴놀린 cgas 길항제 화합물 |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| WO2022246179A1 (en) | 2021-05-21 | 2022-11-24 | Arcus Biosciences, Inc. | Axl inhibitor compounds |
| EP4341261A1 (en) | 2021-05-21 | 2024-03-27 | Arcus Biosciences, Inc. | Axl compounds |
| WO2023077046A1 (en) | 2021-10-29 | 2023-05-04 | Arcus Biosciences, Inc. | Inhibitors of hif-2alpha and methods of use thereof |
| IL315346A (en) | 2022-03-02 | 2024-11-01 | Immunesensor Therapeutics Inc | CGAS agonistic quinoline compounds |
| AU2023264591A1 (en) | 2022-05-02 | 2024-11-07 | Arcus Biosciences, Inc. | Anti-tigit antibodies and uses of the same |
| WO2024015251A1 (en) | 2022-07-15 | 2024-01-18 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| EP4558501A1 (en) | 2022-07-20 | 2025-05-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| US20240180947A1 (en) | 2022-10-20 | 2024-06-06 | Arcus Biosciences, Inc. | Lyophilized formulations of cd73 compounds |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| WO2024233360A1 (en) | 2023-05-05 | 2024-11-14 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| EP4720055A1 (en) | 2023-05-25 | 2026-04-08 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| US20260116868A1 (en) | 2023-10-06 | 2026-04-30 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202523302A (zh) | 2023-11-02 | 2025-06-16 | 美商阿克思生物科學有限公司 | 噻唑化合物及其使用方法 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004092177A1 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolopyrazines and methods of making and using the same |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| US7618962B2 (en) | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| WO2007109547A2 (en) | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
| EP2166854A4 (en) * | 2007-06-13 | 2012-05-16 | Merck Sharp & Dohme | TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| RU2627268C2 (ru) * | 2012-02-29 | 2017-08-04 | Хемоцентрикс, Инк. | Аза-арил-1Н-пиразол-1-ил-сульфонамиды |
| CN105492429A (zh) * | 2013-07-02 | 2016-04-13 | 米伦纽姆医药公司 | Sumo活化酶的杂芳基抑制剂 |
| EP3253390B1 (en) * | 2015-02-06 | 2022-04-13 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
| EP4011882B1 (en) | 2016-08-15 | 2025-03-05 | Purdue Research Foundation | 4-substituted aminoisoquinoline derivatives |
| HUE064141T2 (hu) * | 2017-01-20 | 2024-02-28 | Arcus Biosciences Inc | Azolopirimidin rákkal összefüggõ rendellenességek kezelésére |
-
2019
- 2019-07-26 PL PL19841391.6T patent/PL3829581T3/pl unknown
- 2019-07-26 EP EP19841391.6A patent/EP3829581B1/en active Active
- 2019-07-26 KR KR1020217005878A patent/KR102809468B1/ko active Active
- 2019-07-26 WO PCT/US2019/043608 patent/WO2020023846A1/en not_active Ceased
- 2019-07-26 US US17/263,016 patent/US12064433B2/en active Active
- 2019-07-26 CN CN201980064256.XA patent/CN112996509B/zh active Active
- 2019-07-26 ES ES19841391T patent/ES2982326T3/es active Active
- 2019-07-26 AU AU2019312296A patent/AU2019312296B2/en active Active
- 2019-07-26 JP JP2021504283A patent/JP7394831B2/ja active Active
- 2019-07-26 CA CA3107079A patent/CA3107079A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019312296B2 (en) | 2025-05-29 |
| KR102809468B1 (ko) | 2025-05-19 |
| WO2020023846A1 (en) | 2020-01-30 |
| JP2021531314A (ja) | 2021-11-18 |
| EP3829581A1 (en) | 2021-06-09 |
| US12064433B2 (en) | 2024-08-20 |
| US20210161898A1 (en) | 2021-06-03 |
| EP3829581C0 (en) | 2024-04-03 |
| PL3829581T3 (pl) | 2024-07-01 |
| KR20210038642A (ko) | 2021-04-07 |
| ES2982326T3 (es) | 2024-10-15 |
| AU2019312296A1 (en) | 2021-03-18 |
| EP3829581B1 (en) | 2024-04-03 |
| JP7394831B2 (ja) | 2023-12-08 |
| EP3829581A4 (en) | 2022-04-27 |
| CN112996509B (zh) | 2024-10-01 |
| CN112996509A (zh) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3829581B1 (en) | Pyridone a2r antagonists | |
| EP3618829B1 (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| AU2019379808C1 (en) | Inhibitors of ARG1 and/or ARG2 | |
| US12410170B2 (en) | 2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds | |
| ES2951809T3 (es) | Derivados de quinazolina-pirazol para el tratamiento de trastornos relacionados con el cáncer | |
| AU2019229978B2 (en) | Arginase inhibitors | |
| CA3163338A1 (en) | Inhibitors of hif-2alpha | |
| CA3047600A1 (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| HK40054296A (en) | Pyridone a2r antagonists | |
| HK40054296B (en) | Pyridone a2r antagonists | |
| HK40024629A (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40024629B (en) | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders | |
| HK40055891B (zh) | 吡啶酮a2r拮抗剂 | |
| HK40027765A (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders | |
| HK40027765B (en) | Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220919 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250603 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250603 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250812 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250812 |